Evaluating Nifuroxazide for Ulcerative Colitis Treatment
Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis
This study is testing if adding Nifuroxazide to the usual treatment can help people with mild to moderate ulcerative colitis feel better and improve their quality of life.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Trial ID | NCT05988528 on ClinicalTrials.gov |
What this trial studies
This clinical study aims to evaluate the efficacy of Nifuroxazide in patients diagnosed with mild to moderate ulcerative colitis (UC). The study will involve administering Nifuroxazide alongside Mesalamine to assess its impact on the symptoms and quality of life of participants. Patients will be monitored for improvements in their condition, with a focus on the inflammatory response and gut health. The study is designed to gather data that could lead to better treatment options for those suffering from UC.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a diagnosis of mild to moderate ulcerative colitis.
Not a fit: Patients with severe ulcerative colitis or those with other inflammatory bowel diseases will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new effective treatment option for patients with ulcerative colitis, improving their quality of life.
How similar studies have performed: While there have been studies on various treatments for ulcerative colitis, the specific use of Nifuroxazide in this context is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Both male and female will be * Mild and moderate UC patients diagnosed and confirmed by endoscope Exclusion Criteria: * Breast feeding * Significant liver and kidney function abnormalities * Colorectal cancer patients * Other inflammatory bowel diseases (CD). * Patients with severe UC * Patients taking rectal or systemic steroids * Patients taking immunosuppressives or biological therapies * Addiction to alcohol and / or drugs * Known allergy to the Fenofibrate
Where this trial is running
Tanta
- Tanta University — Tanta, Egypt (Recruiting)
Study contacts
- Study coordinator: Mostafa Bahaa, PhD
- Email: mbahaa@horus.edu.eg
- Phone: 0201025538337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.